Skip to content

STEP-DM

Effect of Lifestyle Management with a Wearable Device (Fitbit) and a Mobile App (TOMOCO) on Glycemic Control in Medicated Patients with Insufficiently Controlled Type 2 Diabetes Mellitus - STEP-DM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1070220007
Enrollment
60
Registered
2022-04-27
Start date
2022-04-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 2

Interventions

Patients use a wearable device (Fitbit) and a lifestyle modification support app (TOMOCO) for 12 weeks.

Sponsors

Kunisaki Makoto
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes mellitus who are visiting the research site as outpatients at the time of screening (SCR). 2. patients >=20 and =7.0% and =65 years old and receiving drugs potentially associated with severe hypoglycemia (e.g. Insulins, sulfonylureas, glinides), HbA1c range of >=7.5% and <8.5% is applied. 7. Patients who have a smart phone device on which apps can be installed, do not plan to change the device during the research period, and agree to the terms and conditions related to the wearable device and the app to be used in this research 8. Patients who have not used a wearable device or lifestyle modification support app for diabetes management or its support within the last 12 weeks prior to SCR. 9. Patients who have given written consent to participate in this research and to provide subject information prior to the research participation.

Exclusion criteria

Exclusion criteria: 1. Female patients who are pregnant, or who wish to become pregnant during the research period 2. Patients diagnosed with or suspected to have type 1 diabetes mellitus, diabetes mellitus due to some other specific mechanism or disease, and gestational diabetes mellitus 3. Patients who have difficulty in controlling blood glucose due to perioperative period or infectious diseases 4. Patients whose diet / exercise therapy is restricted due to comorbidities such as cardio-vascular disease and renal disease 5. Patients who have experienced the need for assistance due to hypoglycemia and are judged by the principal investigator to be difficult to participate in this research 6. Patients with significant changes in blood glucose control during the last 6 months prior to SCR as judged by the investigator 7. Patients who have difficulty with using wearable devices and lifestyle modification support app as judged by the investigator 8. Patients who are likely to require changes in diet/exercise therapy and drug therapy during the research period as judged by the investigator 9. Patients who are participating in other clinical trials, clinical studies, lifestyle-related improvement programs, etc. (excluding observational studies without intervention) 10. Patients who are inappropriate for participation in this research for any other reason such as physical, mental, or social reasons as judged by the investigator

Design outcomes

Primary

MeasureTime frame
Change in HbA1c levels from baseline at 12 weeks

Secondary

MeasureTime frame
Following variables at 12 weeks 1. Patient questionnaire responses 2. Change in body weight

Contacts

Public ContactHideto Awano

EPS Corporation

prj-dm_device@eps.co.jp+81-6-7176-5731

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026